Evidence map›Paper›PMID 32799717›Full record

ArticleImmunological investigations2020

An Immunosuppressive Effect of Melanoma-derived Exosomes on NY-ESO-1 Antigen-specific Human CD8

ShinLa Shu, Junko Matsuzaki, Muzamil Y Want, Alexis Conway, Shawna Benjamin-Davalos, Cheryl L Allen, Marina Koroleva, Sebastiano Battaglia, Adekunle Odunsi, Hans Minderman and 1 more

Open access · greenAbstract read
In one paragraph

Article in Immunological investigations, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. In focus in HCB.Histochemistry and cell biology · 2022
    Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

ShinLa ShuDepartment of Medicine, Roswell Park Comprehensive Cancer Center , Buffalo, NY, USA.
Junko MatsuzakiCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center , Buffalo, NY, USA.
Muzamil Y WantCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center , Buffalo, NY, USA.
Alexis ConwayFlow and Image Cytometry Shared Resource, Roswell Park Comprehensive Cancer Center , Buffalo, NY, USA.
Shawna Benjamin-DavalosDepartment of Medicine, Roswell Park Comprehensive Cancer Center , Buffalo, NY, USA.
Cheryl L AllenDepartment of Medicine, Roswell Park Comprehensive Cancer Center , Buffalo, NY, USA.
Marina KorolevaDepartment of Medicine, Roswell Park Comprehensive Cancer Center , Buffalo, NY, USA.
Sebastiano BattagliaCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center , Buffalo, NY, USA.
Adekunle OdunsiCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center , Buffalo, NY, USA.
Hans MindermanFlow and Image Cytometry Shared Resource, Roswell Park Comprehensive Cancer Center , Buffalo, NY, USA.
Marc S ErnstoffDepartment of Medicine, Roswell Park Comprehensive Cancer Center , Buffalo, NY, USA.
Roswell Park Comprehensive Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
RPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2013 to 2025
$19.6M
Associate-Director Flow and Image Cytometry Roswell Park ComprehensiveCancer CenterR50CA211108 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI HANS MINDERMAN · 2016 to 2026
$3.0M
Imaging Flow CytometerS10OD018048 · OD · ROSWELL PARK CANCER INSTITUTE CORP · PI MINDERMAN, HANS · 2014 to 2014
$400k
NCI NIH HHS P30 CA016056NCI NIH HHS P50 CA159981NCI NIH HHS R50 CA211108NIH HHS S10 OD018048
6 · The paper itself

Abstract

Exosomes, including human melanoma-derived exosomes (HMEX), are known to suppress the function of immune effector cells, which for HMEX has been associated with the surface presence of the immune checkpoint ligand PD-L1. This study investigated the relationship between the BRAF mutational status of melanoma cells and the inhibition of secreted HMEX exosomes on antigen-specific human T cells. Exosomes were isolated from two melanoma cell lines, 2183-Her4 and 888-mel, which are genetically wild-type BRAF

Indexed as

MutationAllelesAmino Acid SubstitutionApoptosisBiomarkers, TumorCD8-Positive T-LymphocytesCell Line, TumorCell SurvivalExosomesFlow CytometryHumansImmune Checkpoint InhibitorsImmune Checkpoint ProteinsImmunomodulationInterleukin-10Protein Kinase InhibitorsBiomarkers, TumorBRAF protein, humanIL10 protein, humanImmune Checkpoint InhibitorsImmune Checkpoint ProteinsInterleukin-10Protein Kinase InhibitorsProto-Oncogene Proteins B-rafexosomesIL-10NY-ESO-1PD-L1 and immunosuppressionT cells

Identifiers

PMID32799717
PMCPMC7816128
OpenAlexW3076931892

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.